Tregalizumab (BT-061) is a humanised monoclonal antibody targeting CD4, capable of binding unique epitopes on CD4 and selectively inducing regulatory T cell (Treg) activation. It holds potential applications in immunology and inflammation.
Purity:
95.00%
CAS Number:
[1207446-68-1]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted